Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 167

1.

mRNA vaccination with charge-altering releasable transporters elicits human T cell responses and cures established tumors in mice.

Haabeth OAW, Blake TR, McKinlay CJ, Waymouth RM, Wender PA, Levy R.

Proc Natl Acad Sci U S A. 2018 Sep 10. pii: 201810002. doi: 10.1073/pnas.1810002115. [Epub ahead of print]

PMID:
30201728
2.

Enhanced mRNA delivery into lymphocytes enabled by lipid-varied libraries of charge-altering releasable transporters.

McKinlay CJ, Benner NL, Haabeth OA, Waymouth RM, Wender PA.

Proc Natl Acad Sci U S A. 2018 Jun 26;115(26):E5859-E5866. doi: 10.1073/pnas.1805358115. Epub 2018 Jun 11.

PMID:
29891683
3.

Characterization of designed, synthetically accessible bryostatin analog HIV latency reversing agents.

Marsden MD, Wu X, Navab SM, Loy BA, Schrier AJ, DeChristopher BA, Shimizu AJ, Hardman CT, Ho S, Ramirez CM, Wender PA, Zack JA.

Virology. 2018 Jul;520:83-93. doi: 10.1016/j.virol.2018.05.006. Epub 2018 May 26.

4.

Functional DNA Delivery Enabled by Lipid-Modified Charge-Altering Releasable Transporters (CARTs).

Benner NL, Near KE, Bachmann MH, Contag CH, Waymouth RM, Wender PA.

Biomacromolecules. 2018 Jul 9;19(7):2812-2824. doi: 10.1021/acs.biomac.8b00401. Epub 2018 May 11.

PMID:
29727572
5.

REDOR NMR Reveals Multiple Conformers for a Protein Kinase C Ligand in a Membrane Environment.

Yang H, Staveness D, Ryckbosch SM, Axtman AD, Loy BA, Barnes AB, Pande VS, Schaefer J, Wender PA, Cegelski L.

ACS Cent Sci. 2018 Jan 24;4(1):89-96. doi: 10.1021/acscentsci.7b00475. Epub 2018 Jan 2.

6.

Gilbert Stork (1921-2017).

Wender PA.

Nature. 2017 Nov 30;551(7682):566. doi: 10.1038/d41586-017-07527-8. No abstract available.

PMID:
29189811
7.

Ynol Ethers as Ketene Equivalents in Rhodium-Catalyzed Intermolecular [5 + 2] Cycloaddition Reactions.

Wender PA, Ebner C, Fennell BD, Inagaki F, Schröder B.

Org Lett. 2017 Nov 3;19(21):5810-5813. doi: 10.1021/acs.orglett.7b02765.

PMID:
29034684
8.

Scalable synthesis of bryostatin 1 and analogs, adjuvant leads against latent HIV.

Wender PA, Hardman CT, Ho S, Jeffreys MS, Maclaren JK, Quiroz RV, Ryckbosch SM, Shimizu AJ, Sloane JL, Stevens MC.

Science. 2017 Oct 13;358(6360):218-223. doi: 10.1126/science.aan7969.

PMID:
29026042
9.

In vivo activation of latent HIV with a synthetic bryostatin analog effects both latent cell "kick" and "kill" in strategy for virus eradication.

Marsden MD, Loy BA, Wu X, Ramirez CM, Schrier AJ, Murray D, Shimizu A, Ryckbosch SM, Near KE, Chun TW, Wender PA, Zack JA.

PLoS Pathog. 2017 Sep 21;13(9):e1006575. doi: 10.1371/journal.ppat.1006575. eCollection 2017 Sep.

10.

Combinations of isoform-targeted histone deacetylase inhibitors and bryostatin analogues display remarkable potency to activate latent HIV without global T-cell activation.

Albert BJ, Niu A, Ramani R, Marshall GR, Wender PA, Williams RM, Ratner L, Barnes AB, Kyei GB.

Sci Rep. 2017 Aug 7;7(1):7456. doi: 10.1038/s41598-017-07814-4.

11.

Bryostatin and its synthetic analog, picolog rescue dermal fibroblasts from prolonged stress and contribute to survival and rejuvenation of human skin equivalents.

Khan TK, Wender PA, Alkon DL.

J Cell Physiol. 2018 Feb;233(2):1523-1534. doi: 10.1002/jcp.26043. Epub 2017 Jul 11.

PMID:
28590053
12.

Molecular dynamics simulations reveal ligand-controlled positioning of a peripheral protein complex in membranes.

Ryckbosch SM, Wender PA, Pande VS.

Nat Commun. 2017 Feb 23;8(1):6. doi: 10.1038/s41467-016-0015-8.

13.

Charge-altering releasable transporters (CARTs) for the delivery and release of mRNA in living animals.

McKinlay CJ, Vargas JR, Blake TR, Hardy JW, Kanada M, Contag CH, Wender PA, Waymouth RM.

Proc Natl Acad Sci U S A. 2017 Jan 24;114(4):E448-E456. doi: 10.1073/pnas.1614193114. Epub 2017 Jan 9.

14.

Vault Nanoparticles: Chemical Modifications for Imaging and Enhanced Delivery.

Benner NL, Zang X, Buehler DC, Kickhoefer VA, Rome ME, Rome LH, Wender PA.

ACS Nano. 2017 Jan 24;11(1):872-881. doi: 10.1021/acsnano.6b07440. Epub 2017 Jan 3.

15.

Comparative analysis of the anti-chikungunya virus activity of novel bryostatin analogs confirms the existence of a PKC-independent mechanism.

Abdelnabi R, Staveness D, Near KE, Wender PA, Delang L, Neyts J, Leyssen P.

Biochem Pharmacol. 2016 Nov 15;120:15-21. doi: 10.1016/j.bcp.2016.09.020. Epub 2016 Sep 21.

16.

Cell-Penetrating, Guanidinium-Rich Oligophosphoesters: Effective and Versatile Molecular Transporters for Drug and Probe Delivery.

McKinlay CJ, Waymouth RM, Wender PA.

J Am Chem Soc. 2016 Mar 16;138(10):3510-7. doi: 10.1021/jacs.5b13452. Epub 2016 Mar 7.

17.

Inhibition of Chikungunya Virus-Induced Cell Death by Salicylate-Derived Bryostatin Analogues Provides Additional Evidence for a PKC-Independent Pathway.

Staveness D, Abdelnabi R, Near KE, Nakagawa Y, Neyts J, Delang L, Leyssen P, Wender PA.

J Nat Prod. 2016 Apr 22;79(4):680-4. doi: 10.1021/acs.jnatprod.5b01017. Epub 2016 Feb 22.

18.

Simplified Bryostatin Analogues Protect Cells from Chikungunya Virus-Induced Cell Death.

Staveness D, Abdelnabi R, Schrier AJ, Loy BA, Verma VA, DeChristopher BA, Near KE, Neyts J, Delang L, Leyssen P, Wender PA.

J Nat Prod. 2016 Apr 22;79(4):675-9. doi: 10.1021/acs.jnatprod.5b01016. Epub 2016 Feb 22.

19.

Cellular delivery and photochemical release of a caged inositol-pyrophosphate induces PH-domain translocation in cellulo.

Pavlovic I, Thakor DT, Vargas JR, McKinlay CJ, Hauke S, Anstaett P, Camuña RC, Bigler L, Gasser G, Schultz C, Wender PA, Jessen HJ.

Nat Commun. 2016 Feb 4;7:10622. doi: 10.1038/ncomms10622.

20.

Bioorthogonal Catalysis: A General Method To Evaluate Metal-Catalyzed Reactions in Real Time in Living Systems Using a Cellular Luciferase Reporter System.

Hsu HT, Trantow BM, Waymouth RM, Wender PA.

Bioconjug Chem. 2016 Feb 17;27(2):376-82. doi: 10.1021/acs.bioconjchem.5b00469. Epub 2015 Sep 25.

21.

Art, architecture, and the molecular frontier.

Wender PA.

Acc Chem Res. 2015 Aug 18;48(8):2169-70. doi: 10.1021/acs.accounts.5b00332. No abstract available.

PMID:
26282016
23.

Studies on the regio- and diastereo-selective epoxidation of daphnanes and tiglianes.

Boudreault PL, Mattler JK, Wender PA.

Tetrahedron Lett. 2015 Jun;56(23):3423-3427.

24.

Tetramethyleneethane Equivalents: Recursive Reagents for Serialized Cycloadditions.

Wender PA, Jeffreys MS, Raub AG.

J Am Chem Soc. 2015 Jul 22;137(28):9088-93. doi: 10.1021/jacs.5b04091. Epub 2015 May 29.

25.

Function through synthesis-informed design.

Wender PA, Quiroz RV, Stevens MC.

Acc Chem Res. 2015 Mar 17;48(3):752-60. doi: 10.1021/acs.accounts.5b00004. Epub 2015 Mar 5.

26.

Toward a biorelevant structure of protein kinase C bound modulators: design, synthesis, and evaluation of labeled bryostatin analogues for analysis with rotational echo double resonance NMR spectroscopy.

Loy BA, Lesser AB, Staveness D, Billingsley KL, Cegelski L, Wender PA.

J Am Chem Soc. 2015 Mar 18;137(10):3678-85. doi: 10.1021/jacs.5b00886. Epub 2015 Mar 4.

28.

Guanidinium-rich, glycerol-derived oligocarbonates: a new class of cell-penetrating molecular transporters that complex, deliver, and release siRNA.

Wender PA, Huttner MA, Staveness D, Vargas JR, Xu AF.

Mol Pharm. 2015 Mar 2;12(3):742-50. doi: 10.1021/mp500581r. Epub 2015 Jan 27.

29.
30.

Improved protein kinase C affinity through final step diversification of a simplified salicylate-derived bryostatin analog scaffold.

Wender PA, Staveness D.

Org Lett. 2014 Oct 3;16(19):5140-3. doi: 10.1021/ol502492b. Epub 2014 Sep 19.

31.

Computer-guided design, synthesis, and protein kinase C affinity of a new salicylate-based class of bryostatin analogs.

Wender PA, Nakagawa Y, Near KE, Staveness D.

Org Lett. 2014 Oct 3;16(19):5136-9. doi: 10.1021/ol502491f. Epub 2014 Sep 19.

32.

Bioengineered vaults: self-assembling protein shell-lipophilic core nanoparticles for drug delivery.

Buehler DC, Marsden MD, Shen S, Toso DB, Wu X, Loo JA, Zhou ZH, Kickhoefer VA, Wender PA, Zack JA, Rome LH.

ACS Nano. 2014 Aug 26;8(8):7723-32. doi: 10.1021/nn5002694. Epub 2014 Jul 31.

33.

Propargyltrimethylsilanes as allene equivalents in transition metal-catalyzed [5 + 2] cycloadditions.

Wender PA, Inagaki F, Pfaffenbach M, Stevens MC.

Org Lett. 2014 Jun 6;16(11):2923-5. doi: 10.1021/ol501114q. Epub 2014 May 12.

34.

Cell-penetrating, guanidinium-rich molecular transporters for overcoming efflux-mediated multidrug resistance.

Vargas JR, Stanzl EG, Teng NN, Wender PA.

Mol Pharm. 2014 Aug 4;11(8):2553-65. doi: 10.1021/mp500161z. Epub 2014 May 9. Review.

35.

Structural complexity through multicomponent cycloaddition cascades enabled by dual-purpose, reactivity regenerating 1,2,3-triene equivalents.

Wender PA, Fournogerakis DN, Jeffreys MS, Quiroz RV, Inagaki F, Pfaffenbach M.

Nat Chem. 2014 May;6(5):448-52. doi: 10.1038/nchem.1917. Epub 2014 Apr 13.

36.

Toward the ideal synthesis and molecular function through synthesis-informed design.

Wender PA.

Nat Prod Rep. 2014 Apr;31(4):433-40. doi: 10.1039/c4np00013g. Epub 2014 Mar 3. Review.

PMID:
24589860
37.
38.

Highly potent, synthetically accessible prostratin analogs induce latent HIV expression in vitro and ex vivo.

Beans EJ, Fournogerakis D, Gauntlett C, Heumann LV, Kramer R, Marsden MD, Murray D, Chun TW, Zack JA, Wender PA.

Proc Natl Acad Sci U S A. 2013 Jul 16;110(29):11698-703. doi: 10.1073/pnas.1302634110. Epub 2013 Jun 28.

39.

Fifteen years of cell-penetrating, guanidinium-rich molecular transporters: basic science, research tools, and clinical applications.

Stanzl EG, Trantow BM, Vargas JR, Wender PA.

Acc Chem Res. 2013 Dec 17;46(12):2944-54. doi: 10.1021/ar4000554. Epub 2013 May 22.

40.
41.

Mechanistic and computational studies of exocyclic stereocontrol in the synthesis of bryostatin-like cis-2,6-disubstituted 4-alkylidenetetrahydropyrans by Prins cyclization.

Ogawa Y, Painter PP, Tantillo DJ, Wender PA.

J Org Chem. 2013 Jan 4;78(1):104-15. doi: 10.1021/jo301953h. Epub 2012 Nov 7.

42.

Designed, synthetically accessible bryostatin analogues potently induce activation of latent HIV reservoirs in vitro.

DeChristopher BA, Loy BA, Marsden MD, Schrier AJ, Zack JA, Wender PA.

Nat Chem. 2012 Sep;4(9):705-10. doi: 10.1038/nchem.1395. Epub 2012 Jul 15.

43.

Designed guanidinium-rich amphipathic oligocarbonate molecular transporters complex, deliver and release siRNA in cells.

Geihe EI, Cooley CB, Simon JR, Kiesewetter MK, Edward JA, Hickerson RP, Kaspar RL, Hedrick JL, Waymouth RM, Wender PA.

Proc Natl Acad Sci U S A. 2012 Aug 14;109(33):13171-6. doi: 10.1073/pnas.1211361109. Epub 2012 Jul 30.

44.

A molecular method for the delivery of small molecules and proteins across the cell wall of algae using molecular transporters.

Hyman JM, Geihe EI, Trantow BM, Parvin B, Wender PA.

Proc Natl Acad Sci U S A. 2012 Aug 14;109(33):13225-30. doi: 10.1073/pnas.1202509109. Epub 2012 Jul 30.

45.

Effect of histone deacetylase inhibitors on HIV production in latently infected, resting CD4(+) T cells from infected individuals receiving effective antiretroviral therapy.

Blazkova J, Chun TW, Belay BW, Murray D, Justement JS, Funk EK, Nelson A, Hallahan CW, Moir S, Wender PA, Fauci AS.

J Infect Dis. 2012 Sep 1;206(5):765-9. doi: 10.1093/infdis/jis412. Epub 2012 Jun 25.

46.

Beyond Cell Penetrating Peptides: Designed Molecular Transporters.

Wender PA, Cooley CB, Geihe EI.

Drug Discov Today Technol. 2012 Spring;9(1):e49-e55.

47.

Ligand effects on rates and regioselectivities of Rh(I)-catalyzed (5 + 2) cycloadditions: a computational study of cyclooctadiene and dinaphthocyclooctatetraene as ligands.

Xu X, Liu P, Lesser A, Sirois LE, Wender PA, Houk KN.

J Am Chem Soc. 2012 Jul 4;134(26):11012-25. doi: 10.1021/ja3041724. Epub 2012 Jun 21.

PMID:
22668243
48.

Taxol-oligoarginine conjugates overcome drug resistance in-vitro in human ovarian carcinoma.

Wender PA, Galliher WC, Bhat NM, Pillow TH, Bieber MM, Teng NN.

Gynecol Oncol. 2012 Jul;126(1):118-23. doi: 10.1016/j.ygyno.2012.03.049. Epub 2012 Apr 6.

49.

Bryostatin analogue-induced apoptosis in mantle cell lymphoma cell lines.

Lopez-Campistrous A, Song X, Schrier AJ, Wender PA, Dower NA, Stone JC.

Exp Hematol. 2012 Aug;40(8):646-56.e2. doi: 10.1016/j.exphem.2012.03.002. Epub 2012 Mar 28.

50.

"Picolog," a synthetically-available bryostatin analog, inhibits growth of MYC-induced lymphoma in vivo.

DeChristopher BA, Fan AC, Felsher DW, Wender PA.

Oncotarget. 2012 Jan;3(1):58-66.

Supplemental Content

Loading ...
Support Center